Aguilera JV, et al. - Preclinical data has shown everolimus (an orally active rapamycin analogue) produces cytostatic cell inhibition, which may be potentially beneficial in treating melanoma. Consequently, researchers assessed the efficacy and safety of everolimus in patients with unresectable metastatic melanoma (MM). In this phase II study, cohort 1 received 30 mg of everolimus by mouth (PO) weekly, and cohort 2 was received 10 mg of everolimus PO daily. For cohort 1, median overall survival was 12.2 months, relative to 8.1 months in cohort 2. Neither group saw a benefit in terms of progression-free survival. Overall, in MM, sufficient single-agent activity was not demonstrated by everolimus, however, evidence of biological activity was found.